Roche is required to document reports of adverse events, both for comprehensive safety monitoring of its products and also to fulfil reporting requirements to Regulatory Authorities. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported.

Reporting of suspected adverse events or reactions (for healthcare professionals)

Reporting suspected adverse events or reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below).

Where possible, healthcare professionals should report adverse events or reactions by brand name and batch number.

M-IE-00001219

Date of preparation: June 2022